or Try an Advanced Search...

    Technical Analysis for PROK - ProKidney Corp.

    Grade Last Price % Change Price Change
    D 3.79 -3.32% -0.13
    PROK closed down 4.85 percent on Wednesday, May 15, 2024, on 1.72 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical PROK trend table...
    Date Alert Name Type % Chg
    Jack-in-the-Box Bullish Bullish Swing Setup -3.32%
    Calm After Storm Range Contraction -3.32%
    Doji - Bearish? Reversal -3.32%
    Upper Bollinger Band Walk Strength -3.32%
    Wide Bands Range Expansion -3.32%
    Above Upper BB Strength -3.32%
    Overbought Stochastic Strength -3.32%
    Upper Bollinger Band Touch Strength -3.32%
    Gapped Down Weakness -3.32%
    Crossed Above 200 DMA Bullish -8.01%
    Older End-of-Day Signals for PROK ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 3 hours ago
    Down 3% about 4 hours ago
    Down 2 % about 4 hours ago
    Down 1% about 4 hours ago
    Fell Below Upper Bollinger Band about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PROK Chart by TradingView
    Basic chart:

    Profile

    ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy

    Is PROK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 11 We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely
    May 10 ProKidney Corp Reports First Quarter 2024 Financial Results
    May 10 ProKidney reports Q1 results
    May 10 ProKidney Reports Business Updates and First Quarter 2024 Financial Results
    Mar 25 ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
    Mar 22 ProKidney GAAP EPS of -$0.57 beats by $0.08
    Mar 21 ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
    Feb 29 ProKidney to Participate in Jefferies Biotech on the Bay Summit
    Dec 29 Chamath Palihapitiya Stocks: 12 Stocks Pumped in the Last 10 Years
    Dec 13 Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now
    See more PROK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.51
    52 Week Low 1.12
    Average Volume 833,518
    200-Day Moving Average 3.37
    50-Day Moving Average 2.01
    20-Day Moving Average 2.58
    10-Day Moving Average 2.79
    Average True Range 0.41
    RSI (14) 73.47
    ADX 32.44
    +DI 41.30
    -DI 7.91
    Chandelier Exit (Long, 3 ATRs) 3.10
    Chandelier Exit (Short, 3 ATRs) 3.18
    Upper Bollinger Bands 3.69
    Lower Bollinger Band 1.48
    Percent B (%b) 1.1
    BandWidth 85.38
    MACD Line 0.40
    MACD Signal Line 0.25
    MACD Histogram 0.1535
    Fundamentals Value
    Market Cap 266.11 Million
    Num Shares 67.9 Million
    EPS -0.58
    Price-to-Earnings (P/E) Ratio -6.76
    Price-to-Sales 0.00
    Price-to-Book 91.32
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.97
    Resistance 3 (R3) 4.99 4.66 4.80
    Resistance 2 (R2) 4.66 4.39 4.65 4.74
    Resistance 1 (R1) 4.29 4.23 4.13 4.27 4.68
    Pivot Point 3.96 3.96 3.88 3.95 3.96
    Support 1 (S1) 3.59 3.69 3.43 3.57 3.16
    Support 2 (S2) 3.26 3.53 3.25 3.10
    Support 3 (S3) 2.89 3.26 3.05
    Support 4 (S4) 2.87